Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YG 1699

Next Previous
Drug Profile

YG 1699

Alternative Names: ABSK101; YG-1699

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Youngene Therapeutics
  • Class Antifibrotics; Antihyperglycaemics; Heart failure therapies; Small molecules
  • Mechanism of Action Sodium-glucose transporter 1 inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus
  • Phase I Diabetic nephropathies; Heart failure
  • Preclinical Cystic fibrosis
  • No development reported Diabetes mellitus

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for phase-I development in Diabetes-mellitus(In volunteers) in China (PO)
  • 18 Oct 2024 Youngene Therapeutics plans a phase I trial for Diabetic neuropathies (Treatment-experience) in China (PO) in October 2024 (NCT06648876)
  • 23 Jun 2023 Pharmacodynamic and pharmacokinetic data from a preclinical trial in Diabetes mellitus presented at the 83rd Annual Scientific Sessions of the American Diabetes Association (ASAD-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top